Cost-Effectiveness of Recombinant Activated Factor VII in the Treatment of Intracerebral Hemorrhage
نویسندگان
چکیده
منابع مشابه
Cost-effectiveness of recombinant activated factor VII in the treatment of intracerebral hemorrhage.
BACKGROUND AND PURPOSE Intracerebral hemorrhage (ICH) is among the most costly and debilitating forms of stroke. Results from a recent Phase IIb clinical trial demonstrate that administration of recombinant activated factor VII (rFVIIa) reduces ICH mortality and improves functional outcome. In the current analysis, we examine the cost-effectiveness of early treatment with rFVIIa for ICH in the ...
متن کاملRecombinant activated factor VII for acute intracerebral hemorrhage
Acute stroke is the third leading cause of death worldwide, exceeded only by coronary artery disease and cancer. There are two major subtypes of strokeischemic and hemorrhagic with 20-30% of all strokes being hemorrhagic in nature. The incidence of ischemic strokes has steadily declined by virtue of rigorous risk factor modification, but the same has not been possible for hemorrhagic strokes. M...
متن کاملRecombinant Activated Factor VII for Acute Intracerebral Hemorrhage
Intracerebral hemorrhage is the least treatable form of stroke and is associated with 30% to 50% mortality rate. Early hematoma growth occurs in 18% to 38% of patients scanned within 3 hours of intracerebral hemorrhage onset, and hematoma volume is an important predictor of poor outcome. Recombinant activated factor VII, a potent initiator of hemostasis, is currently approved for the treatment ...
متن کاملCost effectiveness of recombinant factor VIIa for treatment of intracerebral hemorrhage
BACKGROUND Phase I/II placebo-controlled clinical trials of recombinant Factor VIIa (rFVIIa) suggested that administration of rFVIIa within 4 hours after onset of intracerebral hemorrhage (ICH) is safe, limits ICH growth, and improves outcomes. We sought to determine the cost-effectiveness of rFVIIa for acute ICH treatment, using published Phase II data. We hypothesized that rFVIIa would have a...
متن کاملCan a subset of intracerebral hemorrhage patients benefit from hemostatic therapy with recombinant activated factor VII?
BACKGROUND AND PURPOSE In the Factor Seven for Acute Hemorrhagic Stroke (FAST) trial, 80 microg/kg of recombinant activated factor VII (rFVIIa) significantly reduced intracerebral hemorrhage (ICH) expansion when given within 4 hours of onset. However, in contrast to an earlier Phase 2b study, rFVIIa did not improve survival or functional outcome. In this exploratory analysis, we hypothesized th...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Stroke
سال: 2006
ISSN: 0039-2499,1524-4628
DOI: 10.1161/01.str.0000246611.21999.5d